For instance, in lung cancer, the co-activation of KRAS and c-MYC drives the recruitment of anti-inflammatory macrophages via CCL9 and IL-23, while simultaneously excluding T cells, B cells, and natural killer (NK) cells from the tumor site [145]. Here, KRAS is linked to neoplasm.